How serial medtech entrepreneur, Duke Rohlen, sold FoxHollow Technologies and CV Ingenuity for a combined total of over $1 billion
Welcome to the Medsider interview series, a special new feature at MassDevice, which will appear regularly. All interviews are conducted by Scott Nelson, Founder of Medsider and Partnership Lead at Touch Surgery. We hope you enjoy them! Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter. Why? Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same time – Twitter and Square. Well, medtech’s version of Jack Dorsey might just be Duke Rohlen. Duke led FoxHollow Technologies through an IPO and then later solid it to ev3 for close to $800M. He also founded CV Ingenuity and sold it to Covidien for approximately $300M. Now, similar to Jack Dorsey, Duke is leading 2 early-stage companies at the same time – Spirox and Advanced Cardiac Therapeutics. In this interview with Duke, here are some of the topics and questions we cover: Why the CV Ingenuity team pursued a US-only strategy. Why CV Ingenuity managed their clinical trials internally vs. an outside CRO. Duke’s previous relationships with the leadership at ev3 (now Medtronic) and why they were critical to closing the CV Ingenuity deal with Covidien. How Duke secured a unique $300M collaboration with Merck while serving as President of Fox Hollow Technologies. The major lessons Duke has learned raising money for 4 different medical device companies. The following conversation is based on...
Hi everyone, I am currently a sophomore so I will be applying to vet schools for the first time next year. Recently though I’ve been having a lot of anxiety surrounding applying, getting in, and what happens afterward (I’m a generally anxious person so trying to think about lifelong career choices obviously is not easy). So far I think I have a pretty good shot at getting in (on track for good experience hours, good grades, extracurriculars, etc) but I’m just very worried that I won’t be... Vet med second thoughts
Foods high in soluble fiber like oatmeal, nuts and beans were associated with reduced breast cancer incidence.
Publication date: Available online 4 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Kaili Wang, Weijie Zhang, Zihan Wang, Ming Gao, Xinying Wang, Wenchao Han, Nan Zhang, Xia Xu
Publication date: Available online 5 April 2020Source: Seminars in Cancer BiologyAuthor(s): Emad A. Rakha, Fresia G. Pareja
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Michela Biancolella, Barbara Testa, Leila Baghernajad Salehi, Maria Rosaria D’Apice, Giuseppe Novelli
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Jyoti Gupta, Haaris Ahsan Safdari, Mehboob Hoque
CONCLUSION: Here, we present what, to the best of our knowledge, is the first reported case in which durvarumab resistance after definitive chemoradiotherapy in a patient with stage III pulmonary sarcomatoid carcinoma was overcome by pembrolizumab. PMID: 32245391 [PubMed - as supplied by publisher]
British Journal of Cancer, Published online: 06 April 2020; doi:10.1038/s41416-020-0822-xCombining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
AbstractPurpose of ReviewDetection of BRCA germline mutations (gBRCAm) impacts breast cancer medical treatment —according to differential sensitivity to cytotoxic chemotherapy and the activity of PARP inhibitors—and not only familial prevention. Guidelines for genetic testing—initially mainly based on familial history, age, and triple negative breast cancer (TNBC) subtype—currently are expanding in o rder to offer new therapeutic options.Recent FindingsIn the early setting, gBRCAm patients present a similar outcome as the non-carrier population with standard neoadjuvant chemotherapy, and the role of...